Martin Shkreli: Valeant Worth $28.37/Share

It's no secret Valeant Pharmaceuticals Intl Inc VRX shares had an awful Tuesday. In the afternoon, ex-pharma exec-turned hedge fund manager-turned FBI fraud target Martin Shkreli analyzed the company on his YouTube channel.

According to several tweets recapping the episode, Shkreli valued Valeant at about $28.37 per share. He also added that he doesn't think Valeant is worth shorting, according to Twitter.

Additionally, files publicly shared by Shkreli suggest he's forecasting a gross margin decline for Valeant from 77 percent in 2016 to 70 percent by 2025.

Valeant shares closed Tuesday at $33.54. They were above $200 a year ago.

The live stream is still rolling, below.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Short IdeasHedge FundsMediaTrading IdeasGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!